Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ferrochelating Treatment in Patients Affected by "Neurodegeneration With Brain Iron Accumulation" (NBIA)

Next Previous
Search
Trial Profile

Ferrochelating Treatment in Patients Affected by "Neurodegeneration With Brain Iron Accumulation" (NBIA)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Deferiprone (Primary)
  • Indications Neurodegenerative disorders
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 07 Feb 2023 Status changed from recruiting to active, no longer recruiting.
    • 03 Aug 2022 Planned End Date changed from 1 Dec 2020 to 1 Dec 2024.
    • 03 Aug 2022 Planned primary completion date changed from 1 Dec 2020 to 1 Dec 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top